Novel Therapies in Light Chain Amyloidosis
Light chain (AL) amyloidosis is the most common form of amyloidosis involving the kidney. It is characterized by albuminuria, progressing to overt nephrotic syndrome and eventually end-stage renal failure if diagnosed late or ineffectively treated, and in most cases by concomitant heart involvement....
Main Authors: | Paolo Milani, Giampaolo Merlini, Giovanni Palladini |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-05-01
|
Series: | Kidney International Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024917304539 |
Similar Items
-
LIGHT CHAIN AMYLOIDOSIS
by: Paolo Milani, et al.
Published: (2018-03-01) -
Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
by: Giovanni Palladini, et al.
Published: (2021-03-01) -
The lung in amyloidosis
by: Paolo Milani, et al.
Published: (2017-09-01) -
DUAL expectations in light chain amyloidosis
by: Stefan Schönland, et al.
Published: (2020-07-01) -
Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient
by: Paolo Swuec, et al.
Published: (2019-03-01)